



It's time to eradicate hepatitis C

Sebastian Saville


International Doctors
for
Healthier Drug Policies

Paris 2016

“Striving for Equity”

- Last year it was “pain”
- Next year it will be hepatitis C

Pain meds for 20% - pain for 80%



Striving For Equity



Hepatitis C – first job is to turn off the
tap




How? By treating the source

- Immediate DAA treatment for active injectors most likely to transmit
- Concurrent with solid OST and NSP provision

Increasing treatment uptake with DAAs could result in a substantial decline and even elimination of HCV in Europe by 2025


Total infected cases 2013–2030

Spain




SVR (%)	50	90	90
Rx rate (%)	2.1	2.1	4.5

Germany




SVR (%)	55	90	90
Rx rate (%)	4.7	4.7	9.9

France



SVR (%)	60	90	90
Rx rate (%)	5.2	5.2	10.3

England



SVR (%)	70	93	93
Rx rate (%)	3.8	3.8	14.2

Same trends as countries depicted across Europe

Complete eradication

- 100 million with HCV
- Possible negotiated cost of DAA course - \$500-1000
- Total cost \$50-100 billion

Perspective

- Apple calls 2015 'most successful year ever' after making reported \$234bn



- Firm now has more cash in the bank than the annual GDP of Czech Republic, Peru and New Zealand – over \$205bn

So many famous, wealthy and influential people who have had liver transplants



Striving for equity for access to 84 tablets



More of this

A new WHO report, Global Report on Access to Hepatitis C Treatment: Focus on Overcoming Barriers, released today shows how political will, **civil society advocacy** and **pricing negotiations (!)** are helping address hepatitis C, a disease which kills almost 700 000 people annually and places a heavy burden on health systems' capacities and resources.